- Pataday Once Daily Relief Extra Strength is the first and
only eye allergy itch relief drop offering a full 24 hours of
relief without a prescription in the U.S.1
- The drop, formerly prescribed as Pazeo, joins Alcon’s
over-the-counter ocular allergy portfolio to meet a variety of
patient needs
- The expansion of the Pataday portfolio of products will
strengthen Alcon’s leadership position in the U.S. eye allergy OTC
market
Regulatory News:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210218005372/en/
Pataday Once Daily Relief Extra Strength
now available in select U.S. stores and online retailers (Photo:
Business Wire)
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, today announced that Pataday®
Once Daily Relief Extra Strength (olopatadine hydrochloride
ophthalmic solution 0.7%) is now available in-store and online at
U.S. retailers, following its 2020 approval by the Food and Drug
Administration (FDA) for sale over-the-counter (OTC). As Alcon’s
third Rx-to-OTC switch in the past twelve months, Pataday Once
Daily Relief Extra Strength joins the #1 selling OTC eye allergy
relief brand and is poised to help the company maintain its
leadership position in the ocular allergy market.
“The introduction of Pataday Once Daily Relief Extra Strength
brings a full 24 hours of eye allergy itch relief over the counter
for millions of Americans with eye allergies,” said Sergio Duplan,
President, Alcon North America. “We’re thrilled to provide access
to the strongest concentration of olopatadine, previously the #1
doctor-prescribed eye allergy itch relief ingredient, to consumers
in time for the spring allergy season.”
Approximately 66 million Americans (1 in 5) suffer from ocular
allergies, but only 7 million use an over-the-counter allergy eye
drop to relieve their symptoms.2-5 Alcon’s Pataday portfolio of
products offers fast, long-lasting eye allergy itch relief to the
U.S. population affected by allergic conjunctivitis.6 Pataday Once
Daily Relief Extra Strength provides a full 24 hours of eye allergy
itch relief from pollen, ragweed, grass, animal hair and dander for
people ages two and older with just one drop once a day.
Since 2008, more than 40 million prescriptions were written for
olopatadine, the active ingredient in Pataday.7 Additionally, 58%
of buyers of Pataday Once Daily Relief and Pataday Twice Daily
Relief were new to the OTC eye allergy category.**
“For years, prescription Pazeo was my go-to for patients with
itchy, allergy eyes in need of quick, 24-hour relief. Now, I’m
excited to be able to send them to their retailer of choice for
Pataday Once Daily Relief Extra Strength and the other Pataday
options, confident they’ll find relief despite lifestyle needs,”
said Tania Elliott, M.D., Allergist, New York, NY.***
This launch will be supported by a full-scale media plan,
including online, digital and TV advertising campaigns to reach eye
allergy sufferers and healthcare professionals. Timed with the
product’s mass availability, the campaign will pull through to
digital platforms, in-store activations and partnerships with
celebrity and social media influencers detailing their experiences
with eye allergies and how Pataday Once Daily Relief Extra Strength
is helping them find all day and night relief from itchy allergy
eyes.
Pataday Once Daily Relief Extra Strength is now available in the
U.S. in select stores and via online retailers, such as Amazon,
Walgreens, CVS, Target and more. Widespread commercial availability
will begin this month in all major drug, food and mass-market
retailers.
Visit Pataday.com to learn more.
Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
References
- PAZEO® [package insert]. Fort Worth, TX: Alcon Inc; 2016
- Gomes PJ. Trends in prevalence and treatment of ocular allergy.
Curr Opin Allergy Clin Immunol. 2014; 14: 451-456.
- Singh, K, Axelrod S, Bielory L. The epidemiology of ocular and
nasal allergy in the United States, 1988-1994.
- US Population Census 2019. 6. Nielsen Household Panel Data Feb.
2019.
- Nielsen Latest 52 weeks 2/6/2019
- Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin
Immunol. 2011;11 (5):477-482. 2. Wong AH, Barg SS, Leung AK.
Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm
Allergy Drug Discov. 2009;3(2):118-127. 3. Miraldi Utz V, Kaufman
AR. Allergic eye disease. Pediatr Clin North Am.
2014;61(3):607-620. 4. Singh K, Bielory L. The epidemiology of
ocular and nasal allergy in the United States, 1988-1994. J Allergy
Clin Immunol. 2010;126:778-783.
- Data on file. 2019.
** IRI Data on file *** Dr. Tania Elliott is a paid consultant
for Alcon.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210218005372/en/
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 213 280 9974 (Fort Worth)
globalmedia.relations@alcon.com Investor
Relations Christina Cheng + 41 589 112 110 (Geneva) + 1
817 615 2789 (Fort Worth) investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024